We are live on ! Find out more

1,059 hedge funds and large institutions have $31.6B invested in Biogen in 2026 Q3 according to their latest regulatory filings, with 107 funds opening new positions, 418 increasing their positions, 339 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more first-time investments, than exits

New positions opened: 107 | Existing positions closed: 71

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

23% more repeat investments, than reductions

Existing positions increased: 418 | Existing positions reduced: 339

20% more call options, than puts

Call options by funds: $433M | Put options by funds: $361M

1% more funds holding

Funds holding: 1,051 → 1,059 (+8)

2.09% less ownership

Funds ownership: 96.94% → 94.85% (-2.1%)

16% less capital inflows, than outflows

Capital inflows: $1.92B | Capital outflows: $2.29B

Holders
1,059
Holders Change
+8
Holders Change %
+0.76%
% of All Funds
12.9%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.16%
New
107
Increased
418
Reduced
339
Closed
71
Calls
$433​M
Puts
$361​M
Net Calls
+$71.8​M
Net Calls Change
-⁠$131​M

BIIB Hedge Fund Activity: Q3 2026 in Review

1,059 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2026, worth a combined $31.6B — up 2.4% from $30.9B a quarter earlier.

Buyers outnumbered sellers: 107 funds opened new BIIB positions and 71 closed out — a net gain of 36 holders — while 418 added to existing stakes and 339 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $249M. The largest seller was Fidelity Investments, cutting an estimated $305M.

  • 1,059 institutional investors held Biogen (BIIB) as of Q3 2026, up from 1,051 in Q2 2026.
  • Funds reported $31.6B of Biogen stock for Q3 2026, up 2.4% quarter-over-quarter.
  • 107 funds opened new Biogen positions in Q3 2026 and 71 closed out, a net change of +36 holders.
  • The largest Biogen buyer in Q3 2026 was Citadel Advisors, an estimated $249M added.
  • The largest Biogen seller in Q3 2026 was Fidelity Investments, an estimated $305M sold.

Based on aggregated 13F filings for Q3 2026.